Kintor Pharmaceutical Ltd (HKG: 9939), a biopharmaceutical company based in China, has announced the enrollment of the first patient in a Phase II clinical study for its drug candidate GT20029, which is being investigated for the treatment of acne in China.
The Phase II study is a multi-center, randomized, double-blinded, placebo-controlled trial designed to assess the efficacy, safety, and pharmacokinetics of GT20029 in patients with acne. The study will be conducted across 10 centers in China, with two dosages of the study drug, GT20029 0.5% QD (once daily) and 1.0% QD, being evaluated.
Kintor describes GT20029 as the world’s first topical compound developed using proteolytic targeting chimera (PROTAC) technology. The drug is designed to effectively block the androgen receptor signaling pathway and its physiological functions by degrading the androgen receptor protein. This mechanism of action allows GT20029 to exert local therapeutic effects while minimizing systemic drug exposure, potentially avoiding the side effects associated with oral therapeutic drugs. Positive results have already been observed from a Phase II study of GT20029 in male alopecia.- Flcube.com
